Sökning: id:"swepub:oai:DiVA.org:liu-14379" >
Fcγ receptor type I...
-
Kastbom, AlfÖstergötlands Läns Landsting,Linköpings universitet,Reumatologi,Hälsouniversitetet,Länskliniken för Reumatologi i Östergötland
(författare)
Fcγ receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis
- Artikel/kapitelEngelska2007
Förlag, utgivningsår, omfång ...
-
2007
-
Wiley,2007
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-14379
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-14379URI
-
https://doi.org/10.1002/art.22390DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:12539618URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: To determine whether a functional single-nucleotide polymorphism in the gene encoding Fc receptor type IIIA (FcRIIIA) correlates with the response to treatment with tumor necrosis factor inhibitors in rheumatoid arthritis (RA). Methods: The study population comprised 282 Swedish patients with RA in whom the therapeutic efficacy of conventional disease-modifying antirheumatic drugs had been insufficient. Infliximab or etanercept treatment was initiated, and patients were evaluated after 3 months, using the American College of Rheumatology 20% improvement criteria (ACR20), the ACR50, and the ACR70 or the European League Against Rheumatism (EULAR) criteria. The chi-square test was used to compare response rates across FcRIIIA genotypes. Results: No differences in genotype distribution were observed among nonresponders compared with ACR20 responders (P = 0.80), ACR50 responders (P = 0.56), or ACR70 responders (P = 0.91). Similar results were observed when analyzing infliximab and etanercept separately or when using the EULAR response criteria. Conclusion: Unlike the findings of a previous study, the results of the current study suggest that the 158V/F polymorphism of FcRIIIA is very unlikely to influence the clinical efficacy of infliximab or etanercept in patients with RA.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bratt, JohanKarolinska Institutet
(författare)
-
Ernestam, SofiaKarolinska University Hospital Huddinge and Karolinska Institutet, Stockholm, Sweden
(författare)
-
Lampa, JonKarolinska Institutet
(författare)
-
Padyukov, LeonidKarolinska Institutet
(författare)
-
Söderkvist, PeterLinköpings universitet,Cellbiologi,Hälsouniversitetet(Swepub:liu)petso43
(författare)
-
Skogh, ThomasÖstergötlands Läns Landsting,Linköpings universitet,Reumatologi,Hälsouniversitetet,Länskliniken för Reumatologi i Östergötland(Swepub:liu)thosk00
(författare)
-
Linköpings universitetReumatologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Arthritis and Rheumatism: Wiley56:2, s. 448-4520004-35911529-0131
Internetlänk
Hitta via bibliotek
Till lärosätets databas